The sphingolipid inhibitor myriocin increases Candida auris susceptibility to amphotericin B.
Hanna StieberLara JunghannsHannah WilhelmMaria BatlinerAlexander Maximilian AldejohannOliver KurzaiRonny MartinPublished in: Mycoses (2024)
Our results show that inhibition of de novo sphingolipid biosynthesis increases the susceptibility of C. auris to amphotericin B. This may potentially enhance antifungal treatment options fighting this often resistant yeast pathogen.